Showing 181 - 200 results of 289 for search '"pancreatic cancer"', query time: 0.08s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184

    Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, DNA mutation, and CA199 by Liang Qi, Xiang Li, Jiayao Ni, Yali Du, Qing Gu, Baorui Liu, Jian He, Juan Du

    Published 2025-01-01
    “…Abstract Background Immunotherapy and radiotherapy play crucial roles in the transformation therapy of locally advanced pancreatic cancer; however, the exploration of effective predictive biomarkers has been unsatisfactory. …”
    Get full text
    Article
  5. 185
  6. 186
  7. 187
  8. 188

    Activities of daily living after surgery among older patients with gastrointestinal and hepatobiliary-pancreatic cancers: a retrospective observational study using nationwide health services utilisation data from Japan by Ayako Okuyama, Takahiro Higashi, Hisashi Kosaka, Asao Ogawa, Masaki Kaibori

    Published 2023-05-01
    “…This study aimed to evaluate activities of daily living (ADLs) after oncological surgery in patients with gastrointestinal and hepatobiliary-pancreatic cancers by age groups in Japan.Design Retrospective observational study using health services utilisation data from 1 January 2015 to 31 December 2016.Setting Data for patients with gastrointestinal and hepatobiliary-pancreatic cancers diagnosed in 2015 from 431 hospitals nationwide in Japan.Participants Patients who underwent endoscopic submucosal dissection (ESD), endoscopic mucosal resection (EMR) and laparoscopic or open surgery were included.Outcome measures The proportion of ADL decline at discharge, death and unexpected readmission within 6 weeks postsurgery was calculated by age groups (40–74, 75–79 and ≥80 years).Results Data for 68 032 patients were analysed. …”
    Get full text
    Article
  9. 189

    Evaluation of the Antitumor Effects of Platinum-Based [Pt(η1-C2H4-OR)(DMSO)(phen)]+ (R = Me, Et) Cationic Organometallic Complexes on Chemoresistant Pancreatic Cancer Cell Lines by Erika Stefàno, Luca Giulio Cossa, Federica De Castro, Erik De Luca, Viviana Vergaro, Giulia My, Gianluca Rovito, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi

    Published 2023-01-01
    “…Pancreatic cancer is one of the most lethal malignancies with an increasing incidence and a high mortality rate, due to its rapid progression, invasiveness, and resistance to anticancer therapies. …”
    Get full text
    Article
  10. 190
  11. 191
  12. 192
  13. 193
  14. 194
  15. 195
  16. 196

    Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis by Rongxiang Wu, Zhan Su, Le Zhao, Ruifeng Pei, Yiren Ding, Deqiang Li, Shuo Zhu, Lu Xu, Wei Zhao, Wuyuan Zhou

    Published 2023-01-01
    “…Thus, this study clarified a possible mechanism by which EV-encapsulated NEAT1 from adipose-derived mesenchymal stem cells (ADSCs) might mediate gemcitabine resistance in pancreatic cancer (PCa). Microarray profile suggested a differentially expressed lncRNA NEAT1 in PCa, and we determined its expression in PCa cells. …”
    Get full text
    Article
  17. 197
  18. 198

    Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) by Joachim G J V Aerts, Sjoerd H van der Burg, Martijn P Lolkema, Sai Ping Lau, Freek R van ’t Land, Marjolein Y V Homs, Casper H J van Eijck

    Published 2022-06-01
    “…This study will determine the safety of DC/anti-CD40 agonistic antibody combination treatment, and treatment-induced tumour-specific immunological responses.Methods and analysis In this open-label, single-centre (Erasmus Univsersity Medical Center, Rotterdam, Netherlands), single-arm, phase I dose finding study, adult patients with metastatic pancreatic cancer with progressive disease after FOLFIRINOX chemotherapy will receive monocyte-derived DCs loaded with an allogeneic tumour lysate in conjunction with a CD40 agonistic antibody. …”
    Get full text
    Article
  19. 199

    Diffuse Pancreatic Carcinoma with Hepatic Metastases by Hoang Quan Nguyen, Ngoc Trinh Thi Pham, Van Trung Hoang, Hoang Anh Thi Van, Chinh Huynh, Duc Thanh Hoang

    Published 2020-01-01
    “…Pancreatic cancer is one of the seven leading causes of cancer death worldwide. …”
    Get full text
    Article
  20. 200

    Open and Minimal Approaches to Pancreatic Adenocarcinoma by Ricky H. Bhogal, Stephanos Pericleous, Aamir Z. Khan

    Published 2020-01-01
    “…Surgical options and approaches to pancreatic cancer are changing in the current era. Neoadjuvant treatment strategies for pancreatic cancer combined with the increased use of minimal access surgical techniques mean that the modern pancreatic surgeon requires mastering a number of surgical approaches with to optimally manage patients. …”
    Get full text
    Article